DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Study With Lyrica In Patients Suffering From Epilepsy

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neuralgia; Epilepsy

Intervention: Lyrica (pregabalin) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.

Clinical Details

Official title: Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Percentage of Participants With a 50 Percent or Greater Reduction From Baseline in 28 Day Partial Seizure Frequency

Secondary outcome:

Percentage Change From Baseline in 28 Day Partial Seizure Frequency at Final Visit

Number of Participants With no Seizures (Partial or Other) During the Last 4 Weeks in the Study

Change From Baseline in Visual Analog Scale of Anxiety (VAS-A) Scores at Week 4 and Final Visit

Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)

Number of Participants With Change in Clinical Global Impression of Severity (CGI-C) From Baseline at Final Visit

Change From Baseline in Medical Outcome Study (MOS) Sleep Scale Sub-scores at Week 16 or ET

Detailed description:

- Included all adult patients with partial seizures and without contraindications according

to Summary of Product Characteristics (SmPC).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult patients with partial seizures.

Exclusion Criteria:

- Contraindications according to Summary of Product Characteristics (SmPC).

Locations and Contacts

Pfizer Investigational Site, Banska Bystrica 97401, Slovakia

Pfizer Investigational Site, Banska Bystrica 975 17, Slovakia

Pfizer Investigational Site, Bardejov 08501, Slovakia

Pfizer Investigational Site, Bojnice 97201, Slovakia

Pfizer Investigational Site, Bratislava 1 80101, Slovakia

Pfizer Investigational Site, Bratislava 2 82606, Slovakia

Pfizer Investigational Site, Bratislava 3 83305, Slovakia

Pfizer Investigational Site, Bratislava 4 84104, Slovakia

Pfizer Investigational Site, Bratislava 81369, Slovakia

Pfizer Investigational Site, Bratislava 83103, Slovakia

Pfizer Investigational Site, Cadca 02201, Slovakia

Pfizer Investigational Site, Dolny Kubin 02601, Slovakia

Pfizer Investigational Site, Dubnica nad Vahom 1841, Slovakia

Pfizer Investigational Site, Dunajska Streda 92901, Slovakia

Pfizer Investigational Site, Handlova 97251, Slovakia

Pfizer Investigational Site, Hlohovec 92001, Slovakia

Pfizer Investigational Site, Humenne 06601, Slovakia

Pfizer Investigational Site, Kemarok 06001, Slovakia

Pfizer Investigational Site, Komarno 94501, Slovakia

Pfizer Investigational Site, Kosice 1 04001, Slovakia

Pfizer Investigational Site, Kosice 1 04086, Slovakia

Pfizer Investigational Site, Kosice 2 04011, Slovakia

Pfizer Investigational Site, Kosice 4 04012, Slovakia

Pfizer Investigational Site, Kosice 4 04190, Slovakia

Pfizer Investigational Site, Kosice 04015, Slovakia

Pfizer Investigational Site, Krompachy 05342, Slovakia

Pfizer Investigational Site, Levice 93401, Slovakia

Pfizer Investigational Site, Levoca 05401, Slovakia

Pfizer Investigational Site, Liptovsky Mikulas 03101, Slovakia

Pfizer Investigational Site, Malacky 90122, Slovakia

Pfizer Investigational Site, Martin 03601, Slovakia

Pfizer Investigational Site, Martin 03659, Slovakia

Pfizer Investigational Site, Modra 90001, Slovakia

Pfizer Investigational Site, Myjava 90713, Slovakia

Pfizer Investigational Site, Nitra 94901, Slovakia

Pfizer Investigational Site, Nove Mesto nad Vahom 91501, Slovakia

Pfizer Investigational Site, Nove Zamky 94034, Slovakia

Pfizer Investigational Site, Nove Zamky 94073, Slovakia

Pfizer Investigational Site, Piestany 92101, Slovakia

Pfizer Investigational Site, Poltar 98701, Slovakia

Pfizer Investigational Site, Presov 08001, Slovakia

Pfizer Investigational Site, Puchov 2001, Slovakia

Pfizer Investigational Site, Ruzomberok 03401, Slovakia

Pfizer Investigational Site, Ruzomberok 03426, Slovakia

Pfizer Investigational Site, Sahy 93601, Slovakia

Pfizer Investigational Site, Sered 92601, Slovakia

Pfizer Investigational Site, Skalica 90982, Slovakia

Pfizer Investigational Site, Snina 06901, Slovakia

Pfizer Investigational Site, Spisska Nova Ves 05201, Slovakia

Pfizer Investigational Site, Surany 94218, Slovakia

Pfizer Investigational Site, Trebisov 07501, Slovakia

Pfizer Investigational Site, Trencin 91101, Slovakia

Pfizer Investigational Site, Trnava 91701, Slovakia

Pfizer Investigational Site, Trnava 91775, Slovakia

Pfizer Investigational Site, Trstena 02801, Slovakia

Pfizer Investigational Site, Vranov nad Toplov 09327, Slovakia

Pfizer Investigational Site, Zilina 01001, Slovakia

Pfizer Investigational Site, Zilina 012 07, Slovakia

Pfizer Investigational Site, Zlate Moravce 95301, Slovakia

Pfizer Investigational Site, Zvolen 86001, Slovakia

Pfizer Investigational Site, Zvolen 96001, Slovakia

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2009
Last updated: July 19, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017